Both Tal-DP and Tal-D yielded longer progression-free survival than DPd in those who had received at least one line of therapy ...
Novel targeted therapies for R/R CLL, including venetoclax plus rituximab, acalabrutinib, and zanubrutinib, have favorable safety profiles. Bendamustine plus rituximab showed a lower risk of severe ...
Gastrointestinal prophylaxis reduced Grade ≥ 2 diarrhea/colitis from 55% without prophylaxis to 10% with prophylaxisThe ...
We evaluated patients with relapsed/refractory MM from first-line therapy between 2016–2022, seen at Mayo Clinic, Rochester. All patients had to receive a daratumumab-based treatment as second-line ...
We selected all adult ( ≥18 years) patients diagnosed with DLBCL, tFL, and PMBCL between January 1, 2014, and December 31, 2018―using the International Classification of Diseases for Oncology ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved revumenib for patients aged 1 year and older with relapsed or refractory acute myeloid leukemia ...
Sofi-cel, an allogeneic CAR-T therapy, targets CD7 and uses CRISPR/Cas9 to prevent fratricide and reduce graft-versus-host disease risk. The FDA's breakthrough therapy designation facilitates ...
Johnson & Johnson has welcomed the Scottish Medicines Consortium’s decision to accept Talvey (talquetamab) for use within NHS ...
ORLANDO, Fla. — Adding epcoritamab (Epkinly) to the standard-of-care (SOC) therapy of lenalidomide (Revlimid) and rituximab (Rituxan), a combination known as R 2, lowered the risk for disease ...
The U.S. Food and Drug Administration approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory ...
Belantamab mafodotin, a BCMA-targeting ADC, is approved for relapsed/refractory multiple myeloma after two prior therapies, showing significant PFS and OS benefits in the DREAMM-7 trial. The drug ...
Age-related differences in information-seeking behaviors of patients with multiple myeloma. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not include a full ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results